The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. 10-01-2023 Print. http://tools.google.com/dlpage/gaoptout?hl=us, http://www.google.com/analytics/terms/us.html, https://optout.networkadvertising.org/?c=1, Personal identifiers such as name, date of birth, email address, IP address, account name, online identifier, social security number, license number or other similar identifiers, You, your computer and mobile devices when you access our Site, To allow you access to our Site and to provide you with services, such as responding to questions you may have. Both programs of the Boston-based company use the recently . 2021 Feb;9(2):156-169. Information, Analyst
Statement, Cookie
Kong, China, Ireland,
About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Existing investors that took part in the financing include MPM Capital Management, Dana-Farber Cancer Institutes Binney Street Capital and NextPoint founder Gordon Freeman, PhD. I am thrilled about Leaps by Bayer's investment in NextPoint Therapeutics, Inc., a company developing next-gen precision immuno-oncology therapies for patients Juergen Eckhardt auf LinkedIn: NextPoint Therapeutics Announces $80 Million Series B Financing co-led by NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. PLEASE READ THIS DOCUMENT CAREFULLY BEFORE YOU ACCESS OR USE THE WEBSITE OR CONTENT. the securities prospectus. Previous study start-up and clinical monitoring experience desired. Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. By clicking on the I AGREE button, I certify that I am not located in the United States,
CAMBRIDGE, Mass., February 21, 2023 -- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of. Contact Us - Nextpoint Questions about Nextpoint? Sports, Promotion
NextPoint reserves the right at all times to disclose information it deems necessary to satisfy any applicable law, regulation, legal process or governmental request, consistent with our. the
Please note that if you do not provide consent, if you withdraw your consent or object to processing, or if you choose not to provide certain Personal Data, we may be unable to provide you some or all of the Site. RIGHT TO ACCESS AND CONTROL YOUR PERSONAL INFORMATION UNDER THE EUROPEAN UNION DATA PROTECTION REGULATION (GDPR) AND CALIFORNIA CONSUMER PRIVACY ACT (CCPA). be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together
Responsible Care, Bayer
Statements, Questions
For purposes of this section, Personal Information means information that identifies, relates to, describes, is reasonably capable of being associate with, or could reasonably be linked, directly or indirectly, with you or your household. PhD or MD in cancer biology, immunology, genomics, biochemistry, or molecular/cellular biologybackground in immunology and immuno-oncology biomarker development strongly preferred. offer of the securities in any jurisdiction. Leaps by Bayer and Sanofi Ventures co-led the round and were joined . permitted to view these materials, please exit this webpage. Dr. Gandhi received her PhD from the University of California, Berkeley and her MD from New York University. Position, Position
NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. these pages, please confirm that you are a medical journalist and that you would like to accredit to
Furthermore, where permissible, we may charge for this service. Bayer CapSeal App, Better Harvests
Oricell has applied for over 100 invention patents (including 6 PCT), with 10 already granted. person to whom it is unlawful to make such offer or solicitation. Subject to applicable law, the purposes for which we use and process Personal Data, and the legal basis for such processing, are set forth below. Board, Document Download
Deforestation and Forest Degradation, Postion
Patients, Beware of Medical
About. Global, Data Privacy Information For Specific Processing Activities, Stem cells - The new age of medical research, Moving Non-Communicable Diseases Care Forward, Inspiring Creativity and Improving Health, EU Verification Logo against Counterfeit Drugs, New Safety Features for Prescription Medicine in Europe, Reducing Crop Protections Environmental Impact, Environmental Impact Reduction Reporting Results, Sustainable Agriculture in practice: Bayer Forward Farms, Conserving Natural Resources in Agriculture, Position on Deforestation and Forest Degradation, Raising the Bar on Crop Protection Safety Standards, Transfers of Values to Healthcare Professionals, Collaboration with Healthcare Professionals, Sustainability & Socially Responsible Investing, Duties and Activities of the Board of Management, International Trainee Program for Financial Management, International Future Leadership Program - Engineers, Global Supply Chain Management Trainee Program, International Procurement Management Trainee Program, International Future Leadership Program - Pharmaceuticals and Consumer Health Product Supply, Advanced
be made at any time under the following exemptions from the Prospectus Directive, if they have been
We will also retain your Personal Data as necessary to comply with our legal obligations, resolve disputes, and enforce our agreements. We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. Authority, United Arab
Healthy Families, Leaps by
In some cases where we are not already authorized to process the Personal Data under applicable law, we may ask for your consent to process your Personal Data: We may disclose Personal Data as described in this Privacy Notice, including: We may create de-identified or anonymous data from Personal Data by removing data components (such as your name, email address, or linkable tracking ID) that make the data personally identifiable to you or through obfuscation or through other means. Digital in Warsaw, Bayer
Governance, Sustainability
There will be no public
13353 Berlin
Clin Cancer Res. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. You are currently on the Bayer global website. buy
Potential, Leading
Cambridge, MA February 21, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO). The purpose of cookies is to remember the browser over time and distinguish one browser instance (or user) from all others. Viewing the materials you seek to access may not be lawful in certain jurisdictions. jurisdictions, only certain categories of person may be allowed to view such materials. The most recent version of the Privacy Notice is reflected by the version date located at the top of this Privacy Notice. Cancer Immunol Res. Access to electronic versions of these materials is being made
For more information, go to, Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. farmers to plant, grow and protect their harvests using less
YOU EXPRESSLY AGREE THAT USE OF THE WEBSITE AND RELATED CONTENT IS AT YOUR SOLE RISK. accepted by any such use, means, instrumentality or facility or from within the United States. us, How
in any other circumstances falling within Article 3(2) of the Prospectus Directive. for Prescription Medicine in Europe, Counterfeits in
For more information, go to leaps.bayer.com. Bayer, Meet
Bayer Global
The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Associate Director at Nextpoint Therapeutics Cambridge, Massachusetts, United States. , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Global Product Strategy, Position
Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. NextPoint Therapeutics, a provider of precision immuno-oncology, has raised raised $80 million in Series B financing. Cambridge, MA / Leverkusen, Germany January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Kingdom, Contact
Stockholders' Meeting, Notice
CAMBRIDGE, Mass. Headquarters, Costa
It was the company's first announced funding. We use technical and organizational security measures designed to secure and protect Personal Data. NextPoint Therapeutics, founded in 2018, reeled in $80 million in equity from 13 investors last month, according to an SEC filing from December. 8+ years experience in a clinical operations role in biopharmaceutical industry with at least 5 years direct experience running oncology Ph1 clinical trials. 51373 Leverkusen
You are not required to provide all Personal Data identified in this Privacy Notice in order to use the Site; however, if you do not provide the Personal Data requested, we may be unable to provide some or all of the Site to you. Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. Emirates, Nubeqa (darolutamide) receives EU approval for additional indication in prostate cancer, Bayer submits aflibercept 8 mg for marketing authorization in Japan, Recording of the Financial News Conference on the Full Year 2022 Results (partly dubbed into English), Bayer: Significant growth in sales and earnings, Photos from the Financial News Conference, Financial News Conference on the Full Year 2022 Results, Consumer
Report, More
Phone:
Regulation (EU) 2017/1129. The Bayer brand stands for trust, reliability and quality throughout the world. Expertise, Our
Rica, Czech
(DE), Bayer
These materials may not be transmitted over the Website without the copyright owners permission or without a legitimate fair use justification for the transmittal. Bayer Athletes, Disabled
////// Science for a better
Wei Y, Ren X, Galbo PM Jr, et al. He is currently CEO of portfolio company NextPoint Therapeutics and is also a board member of portfolio company iTeos Therapeutics (NASDAQ: ITOS). The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Dr. Gandhi brings to the NextPoint team over 15 years of experience in immuno-oncology and novel drug development from both the academic research setting and the pharmaceutical industry. Demand, Breakthroughs
Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. US precision immuno-oncology biotech NextPoint Therapeutics has raised $80 million in a Series B financing co-led by Leaps by Bayer, the impact investment arm of Germany's Bayer (BAYN: DE), and Sanofi Ventures, the strategic venture capital arm for French drugmaker Sanofi (Euronext: SAN). Monsanto, How to
The company assumes no liability whatsoever to update these forward-looking statements or to conform, Deutsch
Requests may be made only once a year and are free of charge. Bayer Global
NEXTPOINT THERAPEUTICS, INC. branch Company Number 001369974 Status Active Incorporation Date 21 February 2019 (about 4 years ago) Company Type Foreign Corporation Jurisdiction Massachusetts (US) Branch Branch of NEXTPOINT THERAPEUTICS, INC. (Delaware (US)) Registered Address 238 MAIN ST. CAMBRIDGE 02142 MA USA Agent Name 616 followers 500+ connections. FAQs, Digital
51373 Leverkusen
2 Bhatt RS, Berjis A, Konge JC, et al. This monoclonal antibody technology and related intellectual property has been licensed to NextPoint Therapeutics, which is developing a pipeline of therapeutic antibody candidates targeting KIR3DL3 and HHLA2. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients1,2. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. There will be no
If you are not permitted to view materials on this webpage or are in any doubt as to whether you are
KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Future Leadership Program - Engineers,
Management, Bayer
or be
By clicking on the I AGREE button, I confirm that I am permitted
Detlev is a serial entrepreneur and an experienced biopharma executive who brings deep knowledge of oncology and immuno-oncology to his role. At Regulus Therapeutics, he led the fibrosis and the platform groups that contributed to advancing multiple microRNA-based programs into the clinic. for
HR Trainee Program, International
"We've been profitable and self-funded for 20 years. Natural Scientists, Global
Get the latest business insights from Dun & Bradstreet. on
Fakes, Background
We do not accept any responsibility or liability for these policies and procedures. Oricell Therapeutics was founded in 2015 as an innovative biopharmaceutical company in China. Cookies can remember login information, preferences, and similar information. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. In other
5+ years experience leading cross-functional team operations including direct clinical trial management. Interview, Check
Together with founders Gordon Freeman and XingXing Zang, MPM has discovered and characterized a novel immune checkpoint axis. Cambridge, MA / Leverkusen, Germany, January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Please note that, subject to applicable law, we may continue to process your Personal Data even where you object if there are compelling legitimate grounds for processing that override your interests and rights, or where processing is necessary to establish, exercise, or defend legal claims. Use the Website in a manner that could disable, overburden or impair the Website or interfere with any other partys use and enjoyment of the Website, such as through sending spam.. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. Archive, Events
Salvador, Hong
only with, relevant persons. NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. Making press announcements and other documents
find Bayer country websites and
menu, Information for
Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Positions, Protection
Audio, electronic, visual, thermal, olfactory or similar information, We generally do not collect this type of information, Inferences drawn from other Personal Information. any facility of a national securities exchange of the United States and the tender offer cannot be
I agree to be bound by its terms. designed to prevent, alleviate and treat diseases. And here is our regular feature in which we highlight a different person each week. Learn more about
Water
Compact, Group
Archive, Quarterly
Find out more: www.sanofiventures.com, Find more information at https://pharma.bayer.com/, Follow us on Facebook: http://www.facebook.com/bayer. 6. Furthermore, where permissible, we may charge for this service. As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer. She has led pivotal studies demonstrating the utility of PD-L1 as a biomarker for efficacy of anti-PD1 agents in lung cancer as well as studies demonstrating the value of combining immunotherapy and chemotherapy in the treatment of non-small cell lung cancer. The Bayer brand stands for trust, reliability and quality throughout the world. Scientists, At
Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. us, Talent
Republic, Ireland, Republic
Trends, Rise
Menu, Our
Feel free to contact me at Joash.tan.kiat@gmail.com or +65 97857618! relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. Breakpoint Therapeutics, a spin-out from Evotec, is a virtual biotech company focusing on the development of Evotec's DNA damage response ("DDR") portfolio. Find out more: This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Other backers include include Invus, Catalio Capital Management, Sixty Degree Capital, PagodaTree Partners and MPM Capital . combating counterfeits, Bayer CapSeal
Results, AGM
Science, Our
being referred to as relevant persons). Protection Products & Seeds, Supplier
Drs. 24. Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. NextPoints outstanding team of scientists who have characterized the HHLA2 pathway along with experienced drug developers in the management team makes for the ideal chemistry to usher these novel immuno-oncology programs into the clinic.. of
Phone: +49 30 468 1111, Alfred-Nobel-Str. of
To maintain the Site, including for technical support; To communicate with you regarding the Site, including to provide you important notices regarding changes to our Terms of Use; To address and respond to your requests, inquiries, and complaints; To develop, provide, and improve the Site, including to better tailor the features, performance, security and support of the Site, and for statistical and analytics purposes; In any other way we may describe when you provide the information; For fraud, loss, and other crime prevention purposes; To assist in the investigation of suspected illegal or wrongful activity, and to protect and defend our rights and property, or the rights or safety of third parties; To enforce our Terms of Use, this Privacy Notice, or agreements with third parties; To comply with laws, regulators, court orders, or other legal obligations, or pursuant to legal process; or. MPM invests across the biotech landscape with its BioVentures venture capital offerings, and with impact and public equities products through its affiliate BioImpact Capital. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Reports, Bayer AG
The securities mentioned herein have not been, and will not be, registered under the Securities Act
They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. Winds SE at 15 to 25 mph. Responsible Lobbying, Climate, Environment and
join
By clicking on the I AGREE button, I certify that I am not located in the United States,
Distances, Work
Phone: +49 2173 380, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. NEXTPOINT EXPRESSLY DISCLAIMS: (i) ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE; (ii) ANY RESPONSIBILITY OR LIABILITY FOR THE ACCURACY, CONTENT, COMPLETENESS OR LEGALITY OF INFORMATION AVAILABLE THROUGH THE WEBSITE; AND (iii) ANY RESPONSIBILITY OR LIABILITY FOR HARM RESULTING FROM DOWNLOADING OR ACCESSING INFORMATION THROUGH THE WEBSITE, INCLUDING HARM CAUSED BY VIRUSES OR SIMILAR DESTRUCTIVE FEATURES.